benzyl methyl chlorophosphate | 133660-55-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: benzyl methyl chlorophosphate
• 英文别名: Benzyl methyl phosphorochloridate；[chloro(methoxy)phosphoryl]oxymethylbenzene
• CAS: 133660-55-6
• 化学式: C₈H₁₀ClO₃P
• 分子量: 220.592
• InChiKey: BIPMJGUSVDMMTB-UHFFFAOYSA-N

物化性质

• 沸点：
  311.5±21.0 °C(Predicted)
• 密度：
  1.293±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  benzyl methyl chlorophosphate 在 正丁基锂 、 sodium hydride 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 1.67h， 生成 difluoromethylenebisphosphonic acid benzyl trimethyl ester
  参考文献：
  名称：

  Synthesis of Stable Analogues of Thiamine Di- and Triphosphate as Tools for Probing a New Phosphorylation Pathway

  摘要：

  Thiamine (vitamin B1) is an essential nutritional factor metabolized inside the body in its mono-, di-, and triphosphate forms. Although the action of thiamine and thiamine diphosphate have been intensely investigated, many questions remain unanswered and the role of thiamine triphosphate is still especially unknown. To probe recent hypotheses on the implication of thiamine triphosphate in a new phosphorylation pathway involving synaptic proteins, we synthesized a series of thiamine di- and triphosphate analogues that are resistant to both enzymatic and chemical hydrolyses. The key step in the preparation of the title compounds is the coupling of thiamine propyl disulfide with adequately protected methylenebisphosphonic acid, the corresponding triphosphate analogue, and difluoromethylenebisphosphonic acid.

  DOI：

  10.1002/1521-3765(20021018)8:20<4649::aid-chem4649>3.0.co;2-m
• 作为产物：
  描述：

  dibenzyl methyl phosphate 在 奎宁环 、 草酰氯 作用下， 生成 benzyl methyl chlorophosphate
  参考文献：
  名称：

  从相应的苄基酯方便地“一锅”合成氯代膦酸酯，氯代磷酸酯和氯代磷酰胺

  摘要：

  使用奎尼丁对烷基膦酸酯，磷酸酯和磷酰胺苄基酯进行选择性单脱保护，然后对后续的盐进行氯化，可以方便的“一锅法”制备各种烷基膦酰氯，一氯磷酸酯和一氯磷酰胺。

  DOI：

  10.1016/0040-4039(95)00865-a

文献信息

• PREPARATION OF FOSAMPRENAVIR CALCIUM
  申请人：Mandava Venkata Naga Brahmeshwara Rao

  公开号：US20110224443A1

  公开（公告）日：2011-09-15

  Process for preparation of fosamprenavir and its intermediate salts using novel phthalimide intermediates.

  使用新型邻苯二甲酰亚胺中间体制备福氨普利韦及其中间盐的过程。
• Pharmaceutical formulations comprising indolinone derivatives
  申请人：SUGEN INCORPORATED

  公开号：US20030176399A1

  公开（公告）日：2003-09-18

  The present invention is directed to formulations comprising 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives that modulate the activity of protein kinases (“PKs”). Methods of treating diseases related to abnormal PK activity utilizing the formulations comprising these compounds and methods of making these formulations are also disclosed.

  本发明涉及含有3-(吡咯-2-基甲亚基)-2-吲哚酮衍生物的配方，该配方调节蛋白激酶（“PKs”）的活性。还公开了利用含有这些化合物的配方治疗与异常PK活性相关的疾病的方法，以及制备这些配方的方法。
• Synthesis of diimidotriphosphoric acid and related esters
  作者：Mourad Saady、Luc Lebeau、Charles Mioskowski

  DOI：10.1016/0040-4039(95)00731-q

  日期：1995.6

  The synthesis of diimidotriphosphoric acid and a series of regioselectively protected esters is described. This opens an unprecedented route for the preparation of various nucleotide and dinucleotide analogs and related compounds.

  描述了二亚氨基三磷酸和一系列区域选择性保护的酯的合成。这为制备各种核苷酸和二核苷酸类似物及相关化合物开辟了前所未有的途径。
• Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
  申请人：Moon Wilson Malcolm

  公开号：US20050107340A1

  公开（公告）日：2005-05-19

  The present invention is directed to prodrugs of certain 3-(pyrrol-2-yl-methylidene)-2-indolinone derivatives that modulate the activity of protein kinases (“PKs”). Pharmaceutical compositions comprising these compounds, methods of treating diseases related to abnormal PK activity utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.

  本发明涉及某些3-(吡咯-2-基甲基亚胺基)-2-吲哚酮衍生物的前药，这些衍生物调节蛋白激酶（“PKs”）的活性。本发明还公开了包括这些化合物的制药组合物，利用包括这些化合物的制药组合物治疗与异常PK活性相关的疾病的方法以及制备它们的方法。
• Capsaicinoid prodrug compounds and their use in treating medical conditions
  申请人：Centrexion Therapeutics Corporation

  公开号：US11254659B1

  公开（公告）日：2022-02-22

  The invention provides capsaicinoid prodrug compounds (e.g., prodrugs of resiniferatoxin, tinyatoxin, iodoresiniferatoxin, and related compounds), pharmaceutical compositions, and their use in the treatment of medical conditions, such as pain, and in agonizing TRPV1 activity.

  本发明提供了辣椒素原药化合物（例如，松脂铁毒素、微小铁毒素、碘松脂铁毒素和相关化合物的原药）、药物组合物，以及它们在治疗疼痛等病症和激动TRPV1活性方面的用途。